附录99.1
option care health宣布截至2024年9月30日的第三季度财务业绩。
2024年10月30日，伊利诺州班诺克本。 option care health公司（下称“公司”或“option care health”）（纳斯达克股票代码：OPCH）是全国最大的独立家庭和其他场所输液服务提供商，今天宣布截至2024年9月30日结束的第三季度财务业绩。
2024年第三季财务业绩及亮点
•2023年第三季度净营业收入为$127850万，较$109300万增长17.0%。
•毛利润为25670万美元，占净营业收入的20.1%，较2023年第三季的25430万美元，占营业收入的23.3%，增长1.0%。
•净利润为$5390万，每股摊薄收益为$0.31，较2023年第三季度的净利润$5630万，每股摊薄收益$0.31下降了4.3%。
•调整后的净利润为7070万美元，调整后稀释每股收益为0.41美元，相较于2023年第三季的调整后净利润7310万美元或每股0.40美元下降了3.2%。
•调整后的EBITDA达到11560万美元，较去年同期增长5.3%。 $109.8 2023年第三季的收入达到百万美元。
•营运现金流为16040万美元，比2023年第三季的6100万美元增加。
•2024年第三季末，现金及现金等价物结余为$48300万。
•2024年第三季度回购了约4190万美元的股票
约翰C.拉德马赫（John C. Rademacher），总裁兼首席执行官，评论说：“再次，option care health团队在第三季度以及整个2024年面临多个独特挑战的情况下，继续表现出色，专注于为我们的病人提供非凡的护理。我对我们的团队如何应对自然灾害和恢复工作，以及强劲的第三季度财务结果感到自豪。团队仍然坚韧不拔，并专注于履行我们在2024年承诺，为病人提供一致高质量的护理，并对转诊来源提供可靠的合作伙伴关系。”
Option Care Health宣布，由于飓风海伦的余波，其供应链与静脉输液袋生产有关的混乱，继续影响其支持现有和新患者的能力，主要是在急性治疗组合中。公司会密切监察情况，与制造商和分销商合作，以确保现有的库存。根据目前状况，公司预期该混乱将对第四季度的财务结果产生负面影响，已纳入其2024年更新的指引。目前，Option Care Health无法具体预期供应链混乱对其结果的最终解决时间。
2024年全年财务预测更新
对于2024年整年，option care health现在预计将产生:
•营业收入介于49亿至49.5亿美元。
•调整后的EBITDA介于4.38亿至4.43亿美元之间
•营运现金流至少3亿美元，与先前的指引一致
•26%至28%的有效税率，与先前的指引一致
•净利息费约为5500万至6000万美元，与先前的指引一致
看涨会议通话
Option Care Health将于今天早上8:30 a.m. Et举行一次会议来讨论该公司2024年第三季度的财务结果。可以通过即将在https://investors.optioncarehealth.com线上提供的现场音频网络网络网络收听会议。在通话结束后不久，可以通过现场回播网络网络网络在同一网页链结上随选收听该通话的重播，将持续提供约90天。
关于option care health
option care health是全国最大的独立提供家庭和另类场所输液服务的供应商。拥有包括4500名以上临床医师在内的7500名团队成员，我们以同理心的态度努力提升对于所有50个州的急性和慢性患者的护理标准。通过我们的临床领导力，专业知识和国家规模，option care health正在重新想像患者、客户和团队成员的输液护理体验。欲了解更多资讯，请造访我们的网站： OptionCareHealth.com.
投资者联络方式
| 迈克·夏皮罗 | ||
| 财务长 | ||
| T: (312) 940-2538 | ||
| mike.shapiro@optioncare.com | ||
前瞻性声明－安全港
本新闻稿可能含有根据美国《私人证券诉讼改革法》1995年安全港条款所指的“前瞻性陈述”。前瞻性陈述可通过如下词语辨识：“预期”、“打算”、“计划”、“相信”、“项目”、“估计”、“期待”、“可能”、“应该”、“将”等，并类似地提到未来时段。前瞻性陈述的例子包括，但不限于，我们可能对未来收入、未来盈利、监管发展、市场发展、新产品和增长策略、整合活动以及上述任何事项对我们未来营运结果或财务状况的影响发表的声明。
前瞻性声明既非历史事实，亦非对未来表现的保证。相反，它们仅基于我们目前对业务未来、未来计划和策略、预测、预期事件和趋势、经济状况以及其他未来条件的信念、期望和假设。由于前瞻性声明涉及未来，因此它们面临固有的不确定性、风险和环境变化，这些变化可能难以预测，其中许多是我们无法控制的。我们的实际结果和财务状况可能与前瞻性声明中指示的结果有实质不同。可能导致我们的实际结果和财务状况与前瞻性声明中指示的结果有实质不同的重要因素包括但不限于以下:与我们业务模式相关的法律法规变化；市场条件变化和对我们服务和产品的接受程度；悬而未决以及将来发生的诉讼；潜在的保险未涵盖索赔责任；以及与管理医疗机构和其他非政府第三方支付者的关系丧失。有关可能影响我们实际结果的风险因素的详细讨论，请参阅我们根据证券交易委员会提交的档案中指定的风险因素。
本新闻稿中我们所作的任何前瞻性陈述，仅基于我们目前掌握的信息，并仅代表其发表之日起的情况。我们不承担公开更新任何前瞻性陈述的义务，无论是书面还是口头，可能会不时因新信息、未来发展或其他原因而进行发表。
使用非美国通用会计原则财务指标的注意事项
除了根据普遍接受的会计原则（GAAP）报告财务信息外，公司还报告了调整后的净利润、调整后的EBITDA和调整后的每股收益（"调整后的EPS"），这些均为非GAAP财务指标。这些调整后的指标并非是根据GAAP下的财务表现衡量，不应仅作为净利润、每股收益或任何其他按照GAAP编制的绩效指标的替代品或替代品，也不应仅作为营运活动现金流或公司流动性的替代品或替代品。此外，公司对调整后的净利润、调整后的EBITDA和调整后的EPS的定义可能与其他公司报告的同标题非GAAP财务指标不可比。由公司定义：(i)调整后的净利润表示无形资产摊销费用、股票报酬费用和重组、收购、整合及其他开支的税后调整前净利润(ii)调整后的EBITDA表示净利润前的净利息费用、所得税费用、折旧及摊销、股票报酬费用、债务消灭损失及重组、收购、整合等开支(iii)调整后的每股收益表示调整后的净利润除以加权平均流通股数，按稀释计算。作为重组、收购、整合及其他开支的一部分，公司可能会发生重大费用，例如据实值列示某些长期资产、暂时性多余开支、专业费用、某些诉讼费用和有关已收购业务的备用金、潜在的留任和遣散成本，以及对某些合同义务的潜在加速支付或终止成本。管理层认为这些调整后的指标提供了关于Option Care Health业务运作表现的有用补充信息，并促进与公司历史营运结果的比较。由于对于具体对帐项目的不确定性和可能的变动性，管理层认为未能将调整后EBITDA引导至净利润，因此未创建此对帐。每项调整数据与最相应GAAP财务数据的全面对帐下列所示。
Schedule 1
OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS)(UNAUDITED)
| September 30, 2024 | December 31, 2023 | ||||||||||
| ASSETS | |||||||||||
| CURRENT ASSETS: | |||||||||||
| Cash and cash equivalents | $ | 483,026 | $ | 343,849 | |||||||
| Accounts receivable, net | 428,951 | 377,658 | |||||||||
| Inventories | 310,599 | 274,004 | |||||||||
| Prepaid expenses and other current assets | 98,798 | 98,744 | |||||||||
| Total current assets | 1,321,374 | 1,094,255 | |||||||||
| NONCURRENT ASSETS: | |||||||||||
| Property and equipment, net | 125,911 | 120,630 | |||||||||
| Intangible assets, net | 17,768 | 20,092 | |||||||||
| Referral sources, net | 291,839 | 315,304 | |||||||||
| Goodwill | 1,540,246 | 1,540,246 | |||||||||
| Other noncurrent assets | 130,589 | 126,508 | |||||||||
| Total noncurrent assets | 2,106,353 | 2,122,780 | |||||||||
| TOTAL ASSETS | $ | 3,427,727 | $ | 3,217,035 | |||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
| CURRENT LIABILITIES: | |||||||||||
| Accounts payable | $ | 591,971 | $ | 426,513 | |||||||
| Other current liabilities | 171,253 | 191,796 | |||||||||
| Total current liabilities | 763,224 | 618,309 | |||||||||
| NONCURRENT LIABILITIES: | |||||||||||
| Long-term debt, net of discount, deferred financing costs and current portion | 1,105,106 | 1,056,650 | |||||||||
| Other noncurrent liabilities | 133,166 | 120,404 | |||||||||
| Total noncurrent liabilities | 1,238,272 | 1,177,054 | |||||||||
| Total liabilities | 2,001,496 | 1,795,363 | |||||||||
| STOCKHOLDERS’ EQUITY | 1,426,231 | 1,421,672 | |||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 3,427,727 | $ | 3,217,035 | |||||||
Schedule 2
OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)(UNAUDITED)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| NET REVENUE | $ | 1,278,546 | $ | 1,093,014 | $ | 3,651,784 | $ | 3,177,934 | |||||||||||||||
| COST OF REVENUE | 1,021,797 | 838,748 | 2,907,170 | 2,443,834 | |||||||||||||||||||
| GROSS PROFIT | 256,749 | 254,266 | 744,614 | 734,100 | |||||||||||||||||||
| OPERATING COSTS AND EXPENSES: | |||||||||||||||||||||||
| Selling, general and administrative expenses | 156,999 | 158,214 | 465,524 | 459,644 | |||||||||||||||||||
| Depreciation and amortization expense | 14,659 | 15,005 | 44,294 | 44,417 | |||||||||||||||||||
| Total operating expenses | 171,658 | 173,219 | 509,818 | 504,061 | |||||||||||||||||||
| OPERATING INCOME | 85,091 | 81,047 | 234,796 | 230,039 | |||||||||||||||||||
| OTHER INCOME (EXPENSE): | |||||||||||||||||||||||
| Interest expense, net | (12,345) | (11,786) | (38,150) | (38,816) | |||||||||||||||||||
| Other, net | 808 | 824 | 5,904 | 88,594 | |||||||||||||||||||
| Total other (expense) income | (11,537) | (10,962) | (32,246) | 49,778 | |||||||||||||||||||
| INCOME BEFORE INCOME TAXES | 73,554 | 70,085 | 202,550 | 279,817 | |||||||||||||||||||
| INCOME TAX EXPENSE | 19,698 | 13,783 | 50,860 | 69,904 | |||||||||||||||||||
| NET INCOME | $ | 53,856 | $ | 56,302 | $ | 151,690 | $ | 209,913 | |||||||||||||||
| Earnings per share, basic | $ | 0.32 | $ | 0.31 | $ | 0.88 | $ | 1.17 | |||||||||||||||
| Earnings per share, diluted | $ | 0.31 | $ | 0.31 | $ | 0.87 | $ | 1.16 | |||||||||||||||
| Weighted average common shares outstanding, basic | 170,636 | 178,826 | 172,490 | 179,956 | |||||||||||||||||||
| Weighted average common shares outstanding, diluted | 171,941 | 180,528 | 173,848 | 181,286 | |||||||||||||||||||
Schedule 3
OPTION CARE HEALTH, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)(UNAUDITED)
| Nine Months Ended September 30, | |||||||||||
| 2024 | 2023 | ||||||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | |||||||||||
| Net income | $ | 151,690 | $ | 209,913 | |||||||
| Adjustments to reconcile net income to net cash provided by operations: | |||||||||||
| Depreciation and amortization expense | 46,029 | 46,423 | |||||||||
| Other non-cash adjustments | 54,926 | 54,259 | |||||||||
| Changes in operating assets and liabilities: | |||||||||||
| Accounts receivable, net | (51,293) | (5,075) | |||||||||
| Inventories | (36,595) | (28,362) | |||||||||
| Accounts payable | 164,754 | 50,726 | |||||||||
| Accrued compensation and employee benefits | (31,673) | 4,197 | |||||||||
| Prepaid expenses and other current assets | (3,175) | 3,197 | |||||||||
| Other | (7,393) | (14,952) | |||||||||
| Net cash provided by operating activities | 287,270 | 320,326 | |||||||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | |||||||||||
| Acquisition of property and equipment | (25,266) | (21,981) | |||||||||
| Business acquisitions, net of cash acquired | — | (12,855) | |||||||||
| Other investing activities | — | (5,889) | |||||||||
| Net cash used in investing activities | (25,266) | (40,725) | |||||||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | |||||||||||
| Purchase of company stock | (160,122) | (175,108) | |||||||||
| Proceeds from issuance of debt | 49,959 | — | |||||||||
| Other financing cash flows | (12,664) | (12,190) | |||||||||
| Net cash used in financing activities | (122,827) | (187,298) | |||||||||
| NET INCREASE IN CASH AND CASH EQUIVALENTS | 139,177 | 92,303 | |||||||||
| Cash and cash equivalents - beginning of the period | 343,849 | 294,186 | |||||||||
| CASH AND CASH EQUIVALENTS - END OF PERIOD | $ | 483,026 | $ | 386,489 | |||||||
Schedule 4
OPTION CARE HEALTH, INC.
QUARTERLY RECONCILIATION BETWEEN GAAP AND NON-GAAP MEASURES
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)(UNAUDITED)
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||||||||||
| Net income | $ | 53,856 | $ | 56,302 | $ | 151,690 | $ | 209,913 | |||||||||||||||
| Interest expense, net | 12,345 | 11,786 | 38,150 | 38,816 | |||||||||||||||||||
| Income tax expense | 19,698 | 13,783 | 50,860 | 69,904 | |||||||||||||||||||
| Depreciation and amortization expense | 15,227 | 15,622 | 46,029 | 46,423 | |||||||||||||||||||
| EBITDA | 101,126 | 97,493 | 286,729 | 365,056 | |||||||||||||||||||
| EBITDA adjustments | |||||||||||||||||||||||
| Stock-based incentive compensation | 10,407 | 9,235 | 27,620 | 22,908 | |||||||||||||||||||
| Loss on extinguishment of debt | — | — | 377 | — | |||||||||||||||||||
| Restructuring, acquisition, integration and other (1) | 4,050 | 3,029 | 7,504 | (74,383) | |||||||||||||||||||
| Adjusted EBITDA | $ | 115,583 | $ | 109,757 | $ | 322,230 | $ | 313,581 | |||||||||||||||
| Net income | $ | 53,856 | $ | 56,302 | $ | 151,690 | $ | 209,913 | |||||||||||||||
| Intangible asset amortization expense | 8,596 | 8,641 | 25,809 | 25,752 | |||||||||||||||||||
| Stock-based incentive compensation | 10,407 | 9,235 | 27,620 | 22,908 | |||||||||||||||||||
| Restructuring, acquisition, integration and other (1) | 4,050 | 3,029 | 7,504 | (74,383) | |||||||||||||||||||
| Total pre-tax adjustments | 23,053 | 20,905 | 60,933 | (25,723) | |||||||||||||||||||
| Tax adjustments (2) | (6,178) | (4,118) | (15,294) | 6,431 | |||||||||||||||||||
| Adjusted net income | $ | 70,731 | $ | 73,089 | $ | 197,329 | $ | 190,621 | |||||||||||||||
| Earnings per share, diluted | $ | 0.31 | $ | 0.31 | $ | 0.87 | $ | 1.16 | |||||||||||||||
| Adjusted earnings per share, diluted | $ | 0.41 | $ | 0.40 | $ | 1.14 | $ | 1.05 | |||||||||||||||
| Weighted average common shares outstanding, diluted | 171,941 | 180,528 | 173,848 | 181,286 | |||||||||||||||||||
(1) Restructuring, acquisition, integration and other for the nine months ended September 30, 2023 includes the Amedisys merger termination fee, net of merger-related expenses
(2) Tax adjustments for the three and nine months ended September 30, 2024 and 2023 includes the estimated income tax effect on non-GAAP adjustments based on the effective tax rate